STUDY OF MUTAGENIC POTENTIAL OF RNA-CONTAINING DRUG RN-13 IN AMES TEST
Abstract
The mutagenic properties of the RNA-containing drug RN-13 were studied in the gene mutation induction test (Ames test) on four strains of Salmonella typhimurium TA98, TA100, TA1535, TA1537. No statistically significant dose-dependent increase in the number of revertant colonies was observed for any strain of Salmonella typhimurium in the presence of the study drug in the studied range of doses from 4.0 to 40.0 mg/ml relative to the baseline level of spontaneous mutations. RNA-containing drug RN-13 in the studied dose range for strains TA98, TA100, TA1535, TA1537 Salmonella typhimurium does not have mutagenic activity.
About the Authors
Z. T. Shulgau
National Center for Biotechnology
Russian Federation
Russian Federation
T. N. Krivoruchko
National Center for Biotechnology
Russian Federation
Russian Federation
O. V. Tolmacheva
National Center for Biotechnology
Russian Federation
Russian Federation
S. D. Sergazy
National Center for Biotechnology
Russian Federation
Russian Federation
B. A. Sagindykova
National Center for Biotechnology
Russian Federation
Russian Federation
A. E. Gulyaev
National Center for Biotechnology
Russian Federation
Russian Federation
References
1. Dimmeler S., Nicotera P. MicroRNAs in age-related diseases // EMBO molecular medicine. 2013. Vol. 5. № 2. P. 180-190.
2. Smith-Vikos T., Slack F. J. MicroRNAs and their roles in aging // Journal of cell science. 2012. Vol. 125. P. 7-17.
3. Baumann V., Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents // Future medicinal chemistry. 2014. Vol. 6. № 17. P. 1967-1984.
4. Sehgal A., Vaishnaw A., Fitzgerald K. Liver as a target for oligonucleotide therapeutics // Journal of hepatology. 2013. Vol. 59. Issue 6. P. 1354-1359.
5. Zeliadt N. Big pharma shows signs of renewed interest in RNAi drugs // Nature Medicine. 2014. Vol. 20. № 2. P.109.
6. Stommel G., Schuehlein S., Schuehlein K. H., Rainsford K. D. Therapeutic Effects of Ribunucleinate (Ribonucleotides) in Immuno-Inflammatory and Arthritic Diseases // Prog Drug Res. 2015. Vol. 70. P. 35-89.
7. Sullenger B. A., Gilboa E. Emerging clinical applications of RNA // Nature. 2002. Vol. 418. P. 252-258.
8. Coaker H. Team demonstrates the rational design of drugs from RNA sequence // Future Med Chem. 2014. Vol. 6 (5). P. 495.
9. Ames B. N., McCann J., Yamasaki E. Methods for Detecting Carcinogens and Mutagens with the Salmonella/Mammalian-Microsome Mutagenicity // Test Mutation Res. 1975. Vol. 31. P. 347-364.
10. Maron D. M., Ames B. N. Revised Methods for the Salmonella Mutagenicity Test // Mutation Res. 1983. Vol. 113. P. 173-215.
11. Gatehouse D., Haworth S., Cebula T., Gocke E., Kier L., Matsushima T., Melcion C., Nohmi T., Venitt S., Zeiger E. Recommendations for the Performance of Bacterial Mutation Assays // Mutation Res. 1994. Vol. 312. P. 217-233.
12. Flückiger-Isler S., Kamber M. Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds // Mutation Res. 2012. Vol. 747. № 1. P. 36-45.
13. Kamber M., Flückiger-Isler S., Engelhardt G., Jaeckh R., Zeiger E. Comparison of the Ames II and traditional Ames test responses with respect to mutagenicity, strain specificities, need for metabolism and correlation with rodent carcinogenicity // Mutagenesis. 2009. Vol. 24. № 4. P. 359-366.
Review
For citations:
Shulgau Z.T., Krivoruchko T.N., Tolmacheva O.V., Sergazy S.D., Sagindykova B.A., Gulyaev A.E. STUDY OF MUTAGENIC POTENTIAL OF RNA-CONTAINING DRUG RN-13 IN AMES TEST. Vestnik SurGU. Meditsina. 2017;(4 (34)):67-71. (In Russ.)
Views:
174
Email this article 
